Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Fallopian Tube|Primary Peritoneal Cancer|Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian
Interventions: DRUG: ABT-767
Sponsor: AbbVie (prior sponsor, Abbott)